600420 国药现代
交易中 09-24 14:06:46
资讯
新帖
简况
国药现代(600420.SH)：国药容生维生素B6注射液增加规格并通过一致性评价
智通财经 · 09-22 08:57
国药现代(600420.SH)：国药容生维生素B6注射液增加规格并通过一致性评价
每周股票复盘：国药现代（600420）临时股东会高票通过董事选举
证券之星 · 09-20
每周股票复盘：国药现代（600420）临时股东会高票通过董事选举
国药现代：马来酸依那普利片通过仿制药一致性评价
中国财富通 · 09-18
国药现代：马来酸依那普利片通过仿制药一致性评价
国药现代(600420.SH)：马来酸依那普利片通过一致性评价
智通财经 · 09-17
国药现代(600420.SH)：马来酸依那普利片通过一致性评价
国药现代(600420.SH)：盐酸戊乙奎醚注射液获得药品注册证书
智通财经 · 09-16
国药现代(600420.SH)：盐酸戊乙奎醚注射液获得药品注册证书
每周股票复盘：国药现代（600420）拟每股分红0.1元
证券之星 · 09-13
每周股票复盘：国药现代（600420）拟每股分红0.1元
国药现代(600420.SH)：碳酸氢钠注射液增加规格并通过仿制药一致性评价
智通财经 · 09-12
国药现代(600420.SH)：碳酸氢钠注射液增加规格并通过仿制药一致性评价
国药现代最新公告：全资子公司国药容生获得注射用尼可地尔药品注册证书
证券之星 · 09-01
国药现代最新公告：全资子公司国药容生获得注射用尼可地尔药品注册证书
每周股票复盘：国药现代（600420）2025年中报净利降6.46%
证券之星 · 08-31
每周股票复盘：国药现代（600420）2025年中报净利降6.46%
图解国药现代中报：第二季度单季净利润同比下降19.77%
证券之星 · 08-29
图解国药现代中报：第二季度单季净利润同比下降19.77%
国药现代(600420)6月30日股东户数4万户，较上期减少2.13%
证券之星 · 08-29
国药现代(600420)6月30日股东户数4万户，较上期减少2.13%
化学制药行业21日主力净流出20.79亿元，博腾股份、国药现代居前
金融界 · 08-21
化学制药行业21日主力净流出20.79亿元，博腾股份、国药现代居前
每周股票复盘：国药现代（600420）副总裁李显林因退休离任
证券之星 · 08-09
每周股票复盘：国药现代（600420）副总裁李显林因退休离任
国药现代公布国际专利申请：“自动翻片激光打孔检查机以及打孔方法”
证券之星 · 08-08
国药现代公布国际专利申请：“自动翻片激光打孔检查机以及打孔方法”
国药现代(600420.SH)子公司盐酸氯胺酮原料药获得上市申请批准
智通财经 · 08-07
国药现代(600420.SH)子公司盐酸氯胺酮原料药获得上市申请批准
八月伊始，医药行业 “人事洗牌” 正在上演！涉及华润医药商业、人福医药等
制药网 · 08-06
八月伊始，医药行业 “人事洗牌” 正在上演！涉及华润医药商业、人福医药等
长寿药NMN概念盘中跳水，银禧科技跌0.32%
市场透视 · 08-06
长寿药NMN概念盘中跳水，银禧科技跌0.32%
国药现代最新公告：副总裁李显林因达到退休年龄辞职
证券之星 · 08-03
国药现代最新公告：副总裁李显林因达到退休年龄辞职
每周股票复盘：国药现代（600420）拟挂牌转让国药哈森51%股权
证券之星 · 08-02
每周股票复盘：国药现代（600420）拟挂牌转让国药哈森51%股权
国药现代：公司将积极督促有关承诺方及时履行承诺
互动易 · 08-01
国药现代：公司将积极督促有关承诺方及时履行承诺
加载更多
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":10.81,"timestamp":1758693995000,"preClose":10.75,"halted":0,"volume":6396709,"delay":0,"changeRate":0.0056,"floatShares":1341000000,"shares":1341000000,"eps":0.7734,"marketStatus":"交易中","change":0.06,"latestTime":"09-24 14:06:35","open":10.7,"high":10.83,"low":10.68,"amount":68920000,"amplitude":0.014,"askPrice":10.81,"askSize":196,"bidPrice":10.8,"bidSize":462,"shortable":0,"etf":0,"ttmEps":0.7734,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1758697200000},"marketStatusCode":2,"adr":0,"adjPreClose":10.75,"symbolType":"stock","openAndCloseTimeList":[[1758677400000,1758684600000],[1758690000000,1758697200000]],"highLimit":11.83,"lowLimit":9.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":1.06,"roa":"--","peRate":13.977243,"roe":"4.96%","epsLYR":0.808,"committee":-0.159201,"marketValue":14498000000,"turnoverRate":0.0048,"status":0,"floatMarketCap":14498000000},"requestUrl":"/m/hq/s/600420","defaultTab":"news","newsList":[{"id":"2569074672","title":"国药现代(600420.SH)：国药容生维生素B6注射液增加规格并通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2569074672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569074672?lang=zh_cn&edition=full","pubTime":"2025-09-22 16:57","pubTimestamp":1758531440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团容生制药有限公司(简称国药容生)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准维生素B6注射液增加规格并通过仿制药质量和疗效一致性评价(以下简称一致性评价)，核发药品批准文号。国药容生维生素B6注射液增加规格并通过一致性评价，将有利于该产品未来的市场拓展和销售。上述事项对公司目前经营业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0010","BK0239","BK0020","600420","BK0132"],"gpt_icon":0},{"id":"2569437092","title":"每周股票复盘：国药现代（600420）临时股东会高票通过董事选举","url":"https://stock-news.laohu8.com/highlight/detail?id=2569437092","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569437092?lang=zh_cn&edition=full","pubTime":"2025-09-21 02:37","pubTimestamp":1758393430,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，国药现代报收于10.86元，较上周的11.13元下跌2.43%。本周，国药现代9月18日盘中最高价报11.29元。本周关注点公司公告汇总：2025年第二次临时股东会高票通过《关于选举董事的议案》，同意票占比达99.8439%。公司公告汇总北京市中伦（上海）律师事务所为上海现代制药股份有限公司2025年第二次临时股东会出具法律意见书。出席会议的股东及代理人共422名，代表股份772,689,759股，占公司有表决权股份总数的57.6129%。办法自股东会审议通过后生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0239","600420","BK0020","BK0132","BK0010"],"gpt_icon":0},{"id":"2568515475","title":"国药现代：马来酸依那普利片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2568515475","media":"中国财富通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568515475?lang=zh_cn&edition=full","pubTime":"2025-09-18 18:00","pubTimestamp":1758189650,"startTime":"0","endTime":"0","summary":"9月18日，国药现代（600420）公告称，公司收到国家药监局关于马来酸依那普利片（5mg）的仿制药质量和疗效一致性评价通过通知。该药品主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭。通过此次评价，有利于该产品未来的市场拓展和销售，但对目前经营业绩无重大影响。药品销售受行业政策、招标采购、市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=KKYidXW6%2BI0%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0082","600420","BK0010","BK0132","BK0239","BK0020"],"gpt_icon":0},{"id":"2568636466","title":"国药现代(600420.SH)：马来酸依那普利片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2568636466","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568636466?lang=zh_cn&edition=full","pubTime":"2025-09-17 16:23","pubTimestamp":1758097393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准马来酸依那普利片(5mg)通过仿制药质量和疗效一致性评价。马来酸依那普利片为一种血管紧张素转移酶抑制药，主要用于治疗原发性高血压、肾血管性高血压及症状性心力衰竭等病症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：马来酸依那普利片通过一致性评价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0082","600420","BK0020","BK0239","BK0132"],"gpt_icon":0},{"id":"2567108505","title":"国药现代(600420.SH)：盐酸戊乙奎醚注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2567108505","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567108505?lang=zh_cn&edition=full","pubTime":"2025-09-16 16:53","pubTimestamp":1758012821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，上海现代制药股份有限公司全资子公司国药集团工业有限公司收到国家药品监督管理局核准签发的盐酸戊乙奎醚注射液《药品注册证书》。本次国药工业的盐酸戊乙奎醚注射液获得药品注册证书并视同通过一致性评价，将进一步丰富公司产品群，有利于进一步增强公司的综合市场竞争力，为公司未来发展带来积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0239","BK0020","600420","BK0132","BK0010"],"gpt_icon":0},{"id":"2567135071","title":"每周股票复盘：国药现代（600420）拟每股分红0.1元","url":"https://stock-news.laohu8.com/highlight/detail?id=2567135071","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567135071?lang=zh_cn&edition=full","pubTime":"2025-09-14 04:25","pubTimestamp":1757795111,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，国药现代报收于11.13元，较上周的11.33元下跌1.77%。本周，国药现代9月8日盘中最高价报11.67元。本周关注点公司公告汇总：国药现代拟每股派发现金红利0.10元（含税），股权登记日为2025年9月15日。本次利润分配以公司总股本1,341,172,692股为基数，共计派发现金红利134,117,269.20元。分派对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0239","BK0010","600420","BK0082","BK0132"],"gpt_icon":0},{"id":"2566922373","title":"国药现代(600420.SH)：碳酸氢钠注射液增加规格并通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2566922373","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566922373?lang=zh_cn&edition=full","pubTime":"2025-09-12 16:54","pubTimestamp":1757667269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团容生制药有限公司(以下简称国药容生)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准碳酸氢钠注射液增加规格并通过仿制药质量和疗效一致性评价(以下简称一致性评价)，核发药品批准文号。据悉，碳酸氢钠注射液属于抗酸药，适应症如下：(1)治疗代谢性酸中毒;(2)用于尿酸性肾结石的预防，减少磺胺类药物的肾毒性，及急性溶血防止血红蛋白沉积在肾小管;(3)静脉滴注对某些药物中毒有非特异性的治疗作用，如巴比妥类、水杨酸类药物及甲醇等中毒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0239","600420","BK0132","BK0082","BK0020"],"gpt_icon":0},{"id":"2564813232","title":"国药现代最新公告：全资子公司国药容生获得注射用尼可地尔药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2564813232","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564813232?lang=zh_cn&edition=full","pubTime":"2025-09-01 17:28","pubTimestamp":1756718926,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，全资子公司国药容生收到国家药品监督管理局核准签发的注射用尼可地尔《药品注册证书》。注射用尼可地尔主要适用于治疗不稳定型心绞痛，原研为日本中外制药株式会社，于1993年在日本获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100024026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0010","BK0132","BK0239","BK0020"],"gpt_icon":0},{"id":"2563034835","title":"每周股票复盘：国药现代（600420）2025年中报净利降6.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563034835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563034835?lang=zh_cn&edition=full","pubTime":"2025-08-31 09:50","pubTimestamp":1756605031,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，国药现代报收于11.21元，较上周的11.4元下跌1.67%。本周，国药现代8月26日盘中最高价报11.5元。本周关注点来自业绩披露要点：国药现代2025年中报归母净利润6.72亿元，同比下降6.46%。股本股东变化截至2025年6月30日，国药现代股东户数为4.0万户，较3月31日减少871户，减幅2.13%。拟以股权登记日总股本为基数，每10股派发现金红利1.00元（含税），按2025年6月30日总股本1,341,172,692股计算，合计分配现金股利134,117,269.20元（含税）。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0239","BK0010","BK0020","BK0132"],"gpt_icon":0},{"id":"2563047689","title":"图解国药现代中报：第二季度单季净利润同比下降19.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563047689","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563047689?lang=zh_cn&edition=full","pubTime":"2025-08-29 19:14","pubTimestamp":1756466074,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代2025年中报显示，公司主营收入48.78亿元，同比下降18.16%；归母净利润6.72亿元，同比下降6.46%；扣非净利润6.37亿元，同比下降6.77%；其中2025年第二季度，公司单季度主营收入22.71亿元，同比下降19.95%；单季度归母净利润3.11亿元，同比下降19.77%；单季度扣非净利润2.91亿元，同比下降18.64%；负债率20.32%，投资收益4103.0万元，财务费用-3357.4万元，毛利率36.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900038155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420"],"gpt_icon":0},{"id":"2563048767","title":"国药现代(600420)6月30日股东户数4万户，较上期减少2.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563048767","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563048767?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:17","pubTimestamp":1756459038,"startTime":"0","endTime":"0","summary":"证券之星消息，近日国药现代披露，截至2025年6月30日公司股东户数为4.0万户，较3月31日减少871.0户，减幅为2.13%。在化学制药行业个股中，国药现代股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.29万户。从股价来看，2025年3月31日至2025年6月30日，国药现代区间涨幅为0.47%，在此期间股东户数减少871.0户，减幅为2.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900031970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","600420","BK0020","BK0082","BK0132"],"gpt_icon":0},{"id":"2561100454","title":"化学制药行业21日主力净流出20.79亿元，博腾股份、国药现代居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2561100454","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561100454?lang=zh_cn&edition=full","pubTime":"2025-08-21 15:41","pubTimestamp":1755762116,"startTime":"0","endTime":"0","summary":"8月21日，化学制药行业下跌0.66%，今日主力资金流出20.79亿元，成分股47只上涨，52只下跌。主力资金净流出居前的分别为博腾股份、国药现代、苑东生物、复旦张江、德源药业。序号代码名称最新价涨跌幅主力净流入主力净占比1300573兴齐眼药67.484.691.34亿元8.79%2300705九典制药19.874.971.16亿元11.22%3600276恒瑞医药63.991.811.16亿元2.11%4002020京新药业19.522.91.02亿元16.51%5300199翰宇药业29.952.577618.05万元1.85%6002332仙琚制药11.582.846610.77万元8.64%7002001新 和 成24.132.294818.34万元4.28%8600380健康元12.90.624539.34万元14.53%9002793罗欣药业5.951.883325.33万元12.86%10603229奥翔药业11.631.393097.05万元9.38%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/21154152586844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300363","BK0010","BK1574","BK0082","BK0020","BK0028","BK0239","600420","BK0132","BK1191","01477"],"gpt_icon":0},{"id":"2558507566","title":"每周股票复盘：国药现代（600420）副总裁李显林因退休离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2558507566","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558507566?lang=zh_cn&edition=full","pubTime":"2025-08-10 02:05","pubTimestamp":1754762719,"startTime":"0","endTime":"0","summary":"截至2025年8月8日收盘，国药现代报收于11.29元，较上周的11.39元下跌0.88%。本周，国药现代8月5日盘中最高价报11.54元。国药现代当前最新总市值151.42亿元，在化学制药板块市值排名38/150，在两市A股市值排名1153/5151。本周关注点公司公告汇总：国药现代副总裁李显林因达到退休年龄于2025年8月3日离任公司公告汇总关于高级管理人员离任的公告：李显林先生由于达到退休年龄，已于2025年8月3日辞去公司副总裁及在公司和所属子公司兼任的其他所有职务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081000000324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0239","BK0010","BK0020","BK0132"],"gpt_icon":0},{"id":"2558572043","title":"国药现代公布国际专利申请：“自动翻片激光打孔检查机以及打孔方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2558572043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558572043?lang=zh_cn&edition=full","pubTime":"2025-08-09 05:06","pubTimestamp":1754687168,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示国药现代（600420）公布了一项国际专利申请，专利名为“自动翻片激光打孔检查机以及打孔方法”，专利申请号为PCT/CN2024/085543，国际公布日为2025年8月7日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来国药现代已公布的国际专利申请4个。结合公司2024年年报财务数据，2024年公司在研发方面投入了5.76亿元，同比增1.14%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080900004320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0132","600420","BK0239","BK0010","BK0082"],"gpt_icon":0},{"id":"2557706537","title":"国药现代(600420.SH)子公司盐酸氯胺酮原料药获得上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2557706537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557706537?lang=zh_cn&edition=full","pubTime":"2025-08-07 16:23","pubTimestamp":1754555032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称国药工业)收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准原料药盐酸氯胺酮上市申请。盐酸氯胺酮制剂是一种静脉麻醉药，可作为单一麻醉剂用于无需骨骼肌松弛的诊断和外科手术，也可用于诱导全身麻醉或者作为其他麻醉剂的补充。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1326800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0010","BK0132","600420","BK0239","BK0020"],"gpt_icon":0},{"id":"2557934688","title":"八月伊始，医药行业 “人事洗牌” 正在上演！涉及华润医药商业、人福医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2557934688","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557934688?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:38","pubTimestamp":1754444305,"startTime":"0","endTime":"0","summary":"八月伊始，医药行业风云变幻，华润医药商业、人福医药、天士力、国药现代、科华生物等多家药企纷纷宣布高管变动，一场行业内的 “人事洗牌” 正在上演。8 月 5 日，华润医药商业集团公告，邬建军因职务调整不再担任公司董事及董事长。郭霆同样是华润系老将，其任职足迹遍布华润旗下多家企业，此番代行董事长职责，能否带领华润医药商业开启新的发展篇章，备受瞩目。人福医药在8月1日宣布董事会完成换届选举。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806094144973670e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806094144973670e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","BK0028","BK0185","600420","BK0188","600079","BK0239","BK0070","BK0012","03320"],"gpt_icon":0},{"id":"2557134500","title":"长寿药NMN概念盘中跳水，银禧科技跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557134500","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557134500?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:36","pubTimestamp":1754444210,"startTime":"0","endTime":"0","summary":"08月06日，长寿药NMN概念盘中跳水，截至09点36分，长寿药NMN概念整体指数下跌0.53%，报1236.040点。从个股上来看，该概念的成分股中，银禧科技跌0.32%，百合股份、安琪酵母、国药现代跌幅居前。从资金上来看，截止发稿，长寿药NMN概念主力净流入为2879.04万，其中翰宇药业受到资金热捧，主力净流入3459.33万；拉长时间线来看，该板块近20日主力资金净流入-39.50亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806093650a6d57592&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806093650a6d57592&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064131003.USD","BK0175","BK0028","300221","BK0185","BK0226","BK0138","LU1064130708.USD","LU2148510915.USD","BK0220","603102","LU2580892862.HKD","LU2580892789.USD","BK0188","BK0182","600420","BK0073","600298"],"gpt_icon":0},{"id":"2556221758","title":"国药现代最新公告：副总裁李显林因达到退休年龄辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2556221758","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556221758?lang=zh_cn&edition=full","pubTime":"2025-08-03 15:49","pubTimestamp":1754207388,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司董事会近日收到副总裁李显林的书面辞职申请，李显林因达到退休年龄，申请辞去公司副总裁及在公司和所属子公司兼任的其他所有职务。辞职报告自送达公司董事会之日起生效，李显林离任后将不在公司及所属子公司担任任何职务。上述事项对公司正常的生产经营不会产生影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080300002142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0020","BK0132","BK0082","600420"],"gpt_icon":0},{"id":"2556826255","title":"每周股票复盘：国药现代（600420）拟挂牌转让国药哈森51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2556826255","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556826255?lang=zh_cn&edition=full","pubTime":"2025-08-03 02:00","pubTimestamp":1754157641,"startTime":"0","endTime":"0","summary":"截至2025年8月1日收盘，国药现代报收于11.39元，较上周的11.16元上涨2.06%。截至2025年4月30日，国药哈森资产总额33917.78万元，负债总额18715.00万元，所有者权益15202.78万元。转让完成后，国药哈森将不再纳入公司合并报表范围内。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080300000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600420","BK0132","BK0020","BK0239","BK0082"],"gpt_icon":0},{"id":"2556954768","title":"国药现代：公司将积极督促有关承诺方及时履行承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2556954768","media":"互动易","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556954768?lang=zh_cn&edition=full","pubTime":"2025-08-01 16:27","pubTimestamp":1754036822,"startTime":"0","endTime":"0","summary":"有投资者向国药现代提问， 国药集团于2020年入主太极集团时，便提出在五年内（即2025年10月前）通过资产置换、注入等方式消除西南药业同业竞争。2023年国药集团通过托管方式介入国药现代子公司国瑞药业，并承诺三年内彻底消除其同业竞争问题。领导，您好。目前离集团承诺的日期已不足60天了，目前进度如何了？不会到期后又没人管，没人跟进再往后延迟拖三年吧？希望贵公司抓紧跟进，督促集团说到做到快速解决这些承诺过的事。公司回答表示，尊敬的投资者：您好！公司将积极督促有关承诺方及时履行承诺，并将及时履行信息披露义务。感谢您的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080116415794c8768e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080116415794c8768e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0082","BK0020","600420","BK0010","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758694005180,"stockEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0484},{"period":"3month","weight":0.0352},{"period":"6month","weight":-0.0403},{"period":"1year","weight":0.0873},{"period":"ytd","weight":-0.0749}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.001},{"period":"3month","weight":0.1059},{"period":"6month","weight":0.1328},{"period":"1year","weight":0.3903},{"period":"ytd","weight":0.1402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39950人(较上一季度减少2.13%)","perCapita":"33571股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}